PortfoliosLab logo
AN2 Therapeutics Inc (ANTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

IPO Date

Mar 25, 2022

Highlights

Market Cap

$36.72M

EPS (TTM)

-$1.72

EBITDA (TTM)

-$36.26M

Year Range

$0.87 - $3.07

Target Price

$1.67

Short %

0.44%

Short Ratio

1.07

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in AN2 Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%December2025FebruaryMarchAprilMay
-92.08%
24.67%
ANTX (AN2 Therapeutics Inc)
Benchmark (^GSPC)

Returns By Period

AN2 Therapeutics Inc (ANTX) returned -11.59% year-to-date (YTD) and -50.00% over the past 12 months.


ANTX

YTD

-11.59%

1M

-2.40%

6M

10.91%

1Y

-50.00%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.70%

1M

13.67%

6M

-5.18%

1Y

9.18%

5Y*

14.14%

10Y*

10.43%

*Annualized

Monthly Returns

The table below presents the monthly returns of ANTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-17.39%-0.00%19.30%-8.82%-1.61%-11.59%
2024-5.81%-84.56%9.06%-26.15%-17.08%8.04%18.60%-55.69%-5.31%0.93%54.63%-17.37%-93.27%
202327.60%-7.24%-12.50%-20.47%-28.54%51.52%-4.47%85.22%6.91%-10.32%21.84%16.62%115.01%
2022-2.14%3.72%-4.03%-48.33%10.45%100.23%1.40%-17.03%-30.86%-4.41%-38.12%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ANTX is 23, meaning it’s performing worse than 77% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ANTX is 2323
Overall Rank
The Sharpe Ratio Rank of ANTX is 2020
Sharpe Ratio Rank
The Sortino Ratio Rank of ANTX is 2828
Sortino Ratio Rank
The Omega Ratio Rank of ANTX is 2424
Omega Ratio Rank
The Calmar Ratio Rank of ANTX is 1717
Calmar Ratio Rank
The Martin Ratio Rank of ANTX is 2727
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for AN2 Therapeutics Inc (ANTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current AN2 Therapeutics Inc Sharpe ratio is -0.56. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of AN2 Therapeutics Inc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
-0.56
0.48
ANTX (AN2 Therapeutics Inc)
Benchmark (^GSPC)

Dividends

Dividend History


AN2 Therapeutics Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-94.53%
-7.82%
ANTX (AN2 Therapeutics Inc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AN2 Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AN2 Therapeutics Inc was 95.60%, occurring on Aug 16, 2024. The portfolio has not yet recovered.

The current AN2 Therapeutics Inc drawdown is 94.53%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-95.6%Aug 16, 2022504Aug 16, 2024
-59.56%May 9, 202258Aug 1, 20229Aug 12, 202267
-13.49%Apr 5, 20225Apr 11, 202212Apr 28, 202217
-2.6%Mar 28, 20223Mar 30, 20222Apr 1, 20225
-1.82%Apr 29, 20221Apr 29, 20221May 2, 20222

Volatility

Volatility Chart

The current AN2 Therapeutics Inc volatility is 16.63%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%December2025FebruaryMarchAprilMay
16.63%
11.21%
ANTX (AN2 Therapeutics Inc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AN2 Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of AN2 Therapeutics Inc, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 25.9% positive surprise.


-3.00-2.50-2.00-1.50-1.00-0.50AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-0.25
-0.34
Actual
Estimate

Valuation

The Valuation section provides an overview of how AN2 Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ANTX relative to other companies in the Biotechnology industry. Currently, ANTX has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ANTX in comparison with other companies in the Biotechnology industry. Currently, ANTX has a P/B value of 0.4. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items